A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs

(ACADEMIC)The object of this study was to compare growth factor and cytokine profiles in canine autologous conditioned serum (ACS) to canine plasma. Blood collected from 16 medium to large breed dogs was used to produce ACS (Orthokine ® vet irap 10 syringes) and citrated plasma (control). Canine-specific ELISA assays were run per manufacturers' instructions for interleukin (IL)-10, IL-4, tumor necrosis factor (TNF)-α, insulin-like growth factor (IGF)-1, fibroblast growth factor (FGF)-2, transforming growth factor (TGF)-β1, IL-1β, and interleukin-1 receptor antagonist (IL-1ra). Serum, in addition to plasma and ACS, was collected from an additional 6 dogs for TNF-α, IL-1β, and IL-1ra analysis (total of 22 dogs). Data were analyzed for differences in cytokine concentrations between ACS, plasma, and serum using the Wilcoxon signed-rank test with significance set at P<.05.There was a large variability in growth factor and cytokine concentrations between individual dogs in both plasma and ACS. There were no significant differences in IL-10, TNF-α, IGF-1, FGF-2, and TGF-β1 concentrations between ACS, plasma, or serum. ACS concentrations of IL-1β (median, range; 46.3 pg/mL, 0-828.8) and IL-4 (0.0 pg/mL, 0-244.1) were significantly increased compared to plasma (36.6 pg/mL, 0-657.1 and 0.0 pg/mL, 0-0, respectively). IL-1ra concentrations in ACS (median, range; 3458.9 pg/mL, 1,243.1-12,089.0) were significantly higher than plasma (692.3 pg/mL, 422.5-1,475.6), as was the IL-1ra:IL-1β ratio (39.9 and 7.2, respectively).iii Cytokine and Growth Factor Profiles in Canine Autologous Conditioned SerumDominique Marie Sawyere ABSTRACT (PUBLIC)Osteoarthritis (OA) is a common cause of pain and suffering in dogs and is challenging to treat effectively Current treatment for OA merely mask the signs of pain and do not promote regeneration of the damaged cartilage or alter the course of the disease. Many treatments also cause harmful side effects. Autologous conditioned serum (ACS) is a biological therapy that controls inflammation within the joint by specifically blocking the inflammatory cytokine interleukin (IL)-1β. In humans and horses ACS relieves the pain from OA and promotes cartilage regeneration. The purpose of this study was to compare levels of pro-and anti-inflammatory cytokines in canine ACS to that of normal canine plasma with the hypothesis that levels of anti-inflammatory cytokines would be higher in ACS compared to controls and that levels of pro-inflammatory cytokines would remain unchanged. Paired blood samples were collected from 22 large breed healthy dogs and processed in either irap®10 syringes (ACS) or in anti-coagulant as a control. For the last 6 dogs an additional serum sample was collected. Growth factor and cytokine levels were determined using canine-specific ELISAs. One pro-inflammatory cytokine (IL-1β) and two anti-inflammatory cytokines (IL-1ra and IL-4) were significantly higher in the ACS compared to plasma and IL-1ra levels were also higher in serum compared with plasma samples. Other levels w...

show abstract

“…[181][182][183][184][185] . Depending on the method of production, PRP may also have a leukocyte, red blood cell or fibrin component.…”

Section: Platelet Rich Plasmamentioning

confidence: 99%

Cytokine and Growth Factor Concentrations in Canine Autologous Conditioned Serum

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Dogs with OA may show clinical signs of limping, stiffness of joints, immobility, crepitus, periarticular swelling, and lameness. Pain associated with inflammation appears to be the most serious sign of OA [3,[11][12][13][14][15][16]30]. As stated in the introduction, pathophysiology of OA is very complex due to involvement of multiple factors [18,[20][21][22][23][24][25][26].…”

Section: Discussionmentioning

confidence: 99%

“…Often, large breed dogs (German Shepherds, Labrador Retrievers, Siberian Huskies, Rottweilers, and others) are prone to develop OA (>45%) as compared to smaller breeds [9,10]. Common clinical signs of OA include limping, immobility, stiffness of joints, crepitus, periarticular swelling, and pain upon manipulation of the joint and lameness [3,[11][12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

“…Currently, veterinarians have many options for managing the signs and symptoms of OA, including pharmaceuticals, nutraceuticals, nutrition, surgery, gene therapy, stem cell therapy, laser therapy, physical therapy, and acupuncture [9,15,29,34,[36][37][38][39][40][41]. To alleviate OA associated inflammation and pain, veterinarians often use nonsteroidal anti-inflammatory drugs (NSAIDs), such as carprofen (Rimadyl), meloxicam (Metacam), firocoxib (Previcox), etc., [42,43].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Terminalia chebula Extract for Anti-Arthritic Efficacy and Safety in Osteoarthritic Dogs

Murdock¹,

Vega³

et al. 2015

J Veterinar Sci Technol

View full text Add to dashboard Cite

The present investigation was undertaken to assess anti-inflammatory and anti-arthritic efficacy and safety of T. chebula extract (TCE) in moderately osteoarthritic (OA) dogs. Dogs with OA received either 500 mg placebo or 500 mg TCE twice daily for 150 days. On a monthly basis, dogs were given a full physical exam and were evaluated for arthritic pain (overall pain, pain upon limb manipulation, and pain after physical exertion), inflammation (erythrocyte sedimentation rate, ESR), and analysis of complete blood count (CBC) and serum biomarkers of liver (bilirubin, ALT, and AST), kidney (BUN and creatinine), and heart and skeletal muscle (CK) functions. Elbow and stifle joints were radiographed on day 0 and day 150 for evaluation of arthritic progression. Dogs given TCE showed significant (P<0.01) reductions in overall pain, pain upon limb manipulation, and pain after physical exertion by day 90, with maximum effects on day 150 (81.2%, 81.5%, and 84.2%, respectively). A marked reduction in ESR coincided with pain reduction in TCE-treated dogs, which was indicative of anti-inflammatory effect of TCE. Radiographic evidence also indicated slowed progression of OA in joints examined. No significant change occurred in physical parameters, CBC parameters, or serum biomarkers in dogs on placebo or treatment, which suggested that TCE was well tolerated. It can be concluded that TCE, by having many active principles (chebulagic acid, chebulinic acid, corilagin, hydrolysable tannoids, etc.) might have provided antioxidant, anti-inflammatory and anti-arthritic effects in dogs without causing any side effects.

show abstract

“…These cascading events lead to increased friction and inflammation in the joints. To date, there are no serum, urinary or synovial biomarkers that are specific and validated for OA [18].Common signs and symptoms associated with OA in dogs include limping, immobility, stiffness of joints, crepitus, periarticular swelling, palpable effusion, pain upon manipulation of the joint and lameness [10,[19][20][21][22][23][24][25]. The diagnosis of OA in canine patients is based upon history, physical exam and radiographic evidence.…”

mentioning

confidence: 99%

Anti-Arthritic Efficacy And Safety Of Crominex® 3+ (Trivalent Chromium, Phyllanthus emblica Extract, And Shilajit) In Moderately Arthritic Dogs

Fleck¹,

Rc²,

Jt³

et al. 2014

Journal of Veterinary Science and Animal Husbandry

View full text Add to dashboard Cite

The present investigation was undertaken to evaluate the therapeutic efficacy and safety of Crominex 3+ (a complex of trivalent chromium, Phyllanthus emblica (Amla) extract and purified Shilajit) in moderately arthritic dogs. Eleven client-owned moderately arthritic dogs in a randomized double-blinded study received placebo or Crominex 3+ twice daily for a period of 150 days. On a monthly basis, each dog was evaluated for arthritis associated pain (overall pain, pain upon limb manipulation and pain after physical exertion) and a full physical exam (body weight, body temperature and heart rate). At the same time intervals, dogs serum samples were examined for biomarkers of kidney (BUN and creatinine), liver (bilirubin, ALT and AST) and heart and skeletal muscle (CK) functions. Findings of this investigation revealed that dogs receiving Crominex 3+ (1000 µg chromium, 15 mg Amla extract and 15 mg purified Shilajit per day in two divided doses) exhibited a significant (P<0.05) reduction in arthritic pain noted as early as after 90 days with a maximum reduction after 150 days of treatment. Pain level remained the same or slightly increased in the dogs receiving placebo. No significant change occurred in physical parameters or serum biomarkers in dogs on placebo or Crominex 3+, which suggested that Crominex 3+ was well tolerated by arthritic dogs. In conclusion, Crominex 3+ significantly (P<0.05) ameliorated arthritic pain and improved quality of life without causing any untoward effects in moderately arthritic dogs. [3][4][5]. OA is an inflammatory joint disease characterized by chronic and progressive cartilage degeneration, osteophyte formation, subchondral sclerosis, hypertrophy of bone at the margins and changes in the synovial membrane, which eventually results in decreased stability, movement, loading, stiffness of joints, lameness and pain [6][7][8][9][10][11][12][13][14][15]. Introduction Anti-Arthritic EfficacyIn the early stages of OA, a progressive depletion of the cartilage proteoglycan leads to a net loss of matrix from the cartilage [16,17]. Breakdown and deterioration of the cartilage have been correlated with increased activities of certain enzymes including the matrix metalloproteinase (MMP). The increased cartilage lesions in OA have also been correlated with the enhanced levels of 14,16]. These cascading events lead to increased friction and inflammation in the joints. To date, there are no serum, urinary or synovial biomarkers that are specific and validated for OA [18].Common signs and symptoms associated with OA in dogs include limping, immobility, stiffness of joints, crepitus, periarticular swelling, palpable effusion, pain upon manipulation of the joint and lameness [10,[19][20][21][22][23][24][25]. The diagnosis of OA in canine patients is based upon history, physical exam and radiographic evidence. Finally, MRI findings reveal the changes of joint and cartilage degeneration consistent with OA [26][27][28][29][30].Canines with OA are treated with multipronged approaches, involving i...

show abstract

A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs

Abstract: Results suggested that a single intra-articular injection of autologous platelets resulted in significant improvements at 12 weeks in dogs with osteoarthritis involving a single joint.

Cited by 88 publications

References 33 publications

Cytokine and Growth Factor Concentrations in Canine Autologous Conditioned Serum

Cytokine and Growth Factor Concentrations in Canine Autologous Conditioned Serum

Evaluation of Terminalia chebula Extract for Anti-Arthritic Efficacy and Safety in Osteoarthritic Dogs

Anti-Arthritic Efficacy And Safety Of Crominex® 3+ (Trivalent Chromium, Phyllanthus emblica Extract, And Shilajit) In Moderately Arthritic Dogs

Contact Info

Product

Resources

About